Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis

Antioxidants and Redox Signaling

Volumn 26, Issue 10, 2017, Pages 519-541

  Spahis, Schohraya ^a,b   Delvin, Edgard ^a,b   Borys, Jean Michel ^c   Levy, Emile ^a,b,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c EPODE International Network   (France)

Author keywords

antioxidants; cardiometabolic disorders; liver steatosis; mitochondria; reactive oxygen species; treatment

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BERBERINE; CATECHIN; COLECALCIFEROL; DOCOSAHEXAENOIC ACID; EPIGALLOCATECHIN GALLATE; FLAVONOID; GAMMA TOCOPHEROL; MICRORNA; MYELOPEROXIDASE; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; POLYPHENOL DERIVATIVE; POLYUNSATURATED FATTY ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; RESVERATROL; SILIBININ; SILYMARIN; UBIQUINONE; VITAMIN D; VSL3; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN; PEROXIDASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIET THERAPY; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GENE MUTATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; LIPID DIET; LIPID PEROXIDATION; LIPID STORAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCAVENGING SYSTEM; VITAMIN SUPPLEMENTATION; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS; METABOLISM; MITOCHONDRION; MUTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION REDUCTION REACTION;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BIOMARKERS; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATITIS; HUMANS; LIPOPROTEINS, LDL; MICRORNAS; MITOCHONDRIA; MUTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDASE; REACTIVE OXYGEN SPECIES;

EID: 85016277900     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2016.6776     Document Type: Review

References (256)

1. Aharoni-Simon M, Hann-Obercyger M, Pen S, Madar Z, and Tirosh O. Fatty liver is associated with impaired activity of PPARgamma-coactivator 1alpha (PGC1alpha) and mito-chondrial biogenesis in mice. Lab Invest 91: 1018-1028, 2011.
2. Ahmed T, Gilani AU, Abdollahi M, Daglia M, Nabavi SF, and Nabavi SM. Berberine and neurodegeneration: a review of literature. Pharmacol Rep 67: 970-979, 2015.
3. Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, and Dundar BN. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. Int J Vitam Nutr Res 81: 398-406, 2011.
4. Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, and Daly AK. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 56: 448-454, 2012.
5. Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Jr., and Thompson IM. Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila) 7: 886-895, 2014.
6. Alkhouri N, Carter-Kent C, and Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol 5: 201-212, 2011.
7. Aller R, De Luis DA, Izaola O, Gonzalez Sagrado M, Conde R, Alvarez T, Pacheco D, and Velasco MC. Role of-55CT polymorphism of UCP3 gene on non alcoholic fatty liver disease and insulin resistance in patients with obesity. Nutr Hosp 25: 572-576, 2010.
8. Altinbas A, Sowa JP, Hasenberg T, and Canbay A. The diagnosis and treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 61: 159-169, 2015.
9. Andrade JM, Paraiso AF, de Oliveira MV, Martins AM, Neto JF, Guimaraes AL, de Paula AM, Qureshi M, and Santos SH. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 30: 915-919, 2014.
10. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
11. Aranda JF, Madrigal-Matute J, Rotllan N, and Fernandez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. Free Radic Biol Med 64: 31-39, 2013.
12. Ashraf NU and Sheikh TA. Endoplasmic reticulum stress and oxidative stress in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res 49: 1405-1418, 2015.
13. Aubert J, Begriche K, Knockaert L, Robin MA, and Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 35: 630-637, 2011.
14. Auger C, Teissedre PL, Gerain P, Lequeux N, Bornet A, Serisier S, Besancon P, Caporiccio B, Cristol JP, and Rouanet JM. Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. J Agric Food Chem 53: 2015-2021, 2005.
15. Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Pi-cardi A, Morini S, and Cavallo MG. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepa-tology 56: 2180-2187, 2012.
16. Baur JA and Sinclair DA. Therapeutic potential of re-sveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
17. Beal MF and Matthews RT. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med 18 Suppl: S169-S179, 1997.
18. Bellentani S, Scaglioni F, Marino M, and Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28: 155-161, 2010.
19. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, and Pessayre D. Steatohepatitis-inducing drugs cause mito-chondrial dysfunction and lipid peroxidation in rat hepa-tocytes. Gastroenterology 114: 764-774, 1998.
20. Bieghs V, van Gorp PJ, Walenbergh SM, Gijbels MJ, Ver-heyen F, Buurman WA, Briles DE, Hofker MH, Binder CJ, and Shiri-Sverdlov R. Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology 56: 894-903, 2012.
21. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJ, de Winther MP, Binder CJ, Lutjohann D, Febbraio M, Moore KJ, van Bilsen M, Hofker MH, and Shiri-Sverdlov R. Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastro-enterology 138: 2477-2486, 2486 e1-e3, 2010.
22. Bouzianas DG, Bouziana SD, and Hatzitolios AI. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev 71: 753-771, 2013.
23. Bravo E, Palleschi S, Rossi B, Napolitano M, Tiano L, D'Amore E, and Botham KM. Coenzyme Q metabolism is disturbed in high fat diet-induced non-alcoholic fatty liver disease in rats. Int J Mol Sci 13: 1644-1657, 2012.
24. Bril F, Sninsky JJ, Baca AM, Robert Superko H, Portillo Sanchez P, Biernacki D, Maximos M, Lomonaco R, Orsak B, Suman A, Weber MH, McPhaul MJ, and Cusi K. Hepatic steatosis and insulin resistance, but not steatohepa-titis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 101: 644-652, 2016.
25. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, and Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395, 2004.
26. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, and Issandou M. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47: 1281-1288, 2006.
27. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, Garcia-Urkia N, Sarasqueta C, Cosme A, Irastorza B, Gonzalez A, and Arenas JI, Jr. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 8: 40, 2008.
28. Butt MS and Sultan MT. Green tea: nature's defense against malignancies. Crit Rev Food Sci Nutr 49: 463-473, 2009.
29. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, He-spenheide EE, Parks JK, and Parker WD, Jr. Mitochon-drial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31: 430-434, 1999.
30. Cano A, Ciaffoni F, Safwat GM, Aspichueta P, Ochoa B, Bravo E, and Botham KM. Hepatic VLDL assembly is disturbed in a rat model of nonalcoholic fatty liver disease: is there a role for dietary coenzyme Q? J Appl Physiol (1985) 107: 707-717, 2009.
31. Cao SS and Kaufman RJ. Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal 21: 396-413, 2014.
32. Chalasani N, Deeg MA, and Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99: 1497-1502, 2004.
33. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, and Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592-1609, 2012.
34. Chang CJ, Tzeng TF, Liou SS, Chang YS, and Liu IM. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARalpha levels. Planta Med 77: 1876-1882, 2011.
35. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, and Mi M. Resveratrol im-proves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis 47: 226-232, 2015.
36. Chitranjali T, Anoop Chandran P, and Muraleedhara Kurup G. Omega-3 fatty acid concentrate from Dunaliella salina possesses anti-inflammatory properties including blockade of NF-kappaB nuclear translocation. Im-munopharmacol Immunotoxicol 37: 81-89, 2015.
37. Chiu KC, Chu A, Go VL, and Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79: 820-825, 2004.
38. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, and Hayes JD. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48: 357-371, 2010.
39. Cicero AF, Rosticci M, Parini A, Morbini M, Urso R, Grandi E, and Borghi C. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J 14: 30, 2015.
40. Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, and Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60: 360-367, 2015.
41. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, and Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282: 1659-1664, 1999.
42. Cullinan SB and Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem 279: 20108-20117, 2004.
43. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 50: 585-588, 2002.
44. Day CP and James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 27: 1463-1466, 1998.
45. Day CP and James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998.
46. de Wit NJ, Afman LA, Mensink M, and Muller M. Phe-notyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol 57: 1370-1373, 2012.
47. Deckelbaum RJ, Worgall TS, and Seo T. n-3 fatty acids and gene expression. Am J Clin Nutr 83: 1520S-1525S, 2006.
48. Del Ben M, Baratta F, Polimeni L, and Angelico F. Nonalcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med 7 Suppl 3: S291-S296, 2012.
49. Del Ben M, Polimeni L, Baratta F, Bartimoccia S, Car-nevale R, Loffredo L, Pignatelli P, Violi F, and Angelico F. Serum cytokeratin-18 is associated with NOX2-generated oxidative stress in patients with nonalcoholic fatty liver. Int J Hepatol 2014: 784985, 2014.
50. Del Ben M, Polimeni L, Carnevale R, Bartimoccia S, Nocella C, Baratta F, Loffredo L, Pignatelli P, Violi F, and Angelico F. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 14: 81, 2014.
51. Deltour L, Foglio MH, and Duester G. Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3, and Adh4 null mutant mice. Overlapping roles of Adh1 and Adh4 in ethanol clearance and metabolism of retinol to retinoic acid. J Biol Chem 274: 16796-16801, 1999.
52. Dentin R, Benhamed F, Hainault I, Fauveau V, Foufelle F, Dyck JR, Girard J, and Postic C. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resis-tance in ob/ob mice. Diabetes 55: 2159-2170, 2006.
53. Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A, and Wands JR. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 58: 785-791, 2013.
54. Di Minno MN, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, and Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 18: 5839-5847, 2012.
55. Diehl AM. Lessons from animal models of NASH. He-patol Res 33: 138-144, 2005.
56. Dong SF, Yasui N, Negishb H, Kishimoto A, Sun JN, and Ikeda K. Increased oxidative stress in cultured 3T3-L1 cells was attenuated by berberine treatment. Nat Prod Commun 10: 895-897, 2015.
57. Dowman JK, Armstrong MJ, Tomlinson JW, and Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 13: 692-702, 2011.
58. Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, and Thummel KE. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 38: 428-435, 2003.
59. Eraslan S, Kizilgul M, Uzunlulu M, Colak Y, Ozturk O, and Tuncer I. Frequency of metabolic syndrome and 25-hydroxyvitamin D3 levels in patients with non-alcoholic fatty liver disease. Minerva Med 104: 447-453, 2013.
60. Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, and Haussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH). Eur J Med Res 16: 76-78, 2011.
61. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, and Hekmatdoost A. Synbiotic supple-mentation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 99: 535-542, 2014.
62. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, and Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 139: 905-911, 2009.
63. Faghihzadeh F, Adibi P, Rafiei R, and Hekmatdoost A. Resveratrol supplementation improves inflammatory bio-markers in patients with nonalcoholic fatty liver disease. Nutr Res 34: 837-843, 2014.
64. Farhangi MA, Alipour B, Jafarvand E, and Khoshbaten M. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch Med Res 45: 589-595, 2014.
65. Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, and Engali KA. Functions of coenzyme Q10 supplementation on liver enzymes, markers of systemic inflammation, and adipokines in patients affected by nonalcoholic fatty liver disease: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr 35: 346-353, 2016.
66. Feillet-Coudray C, Aoun M, Fouret G, Bonafos B, Ramos J, Casas F, Cristol JP, and Coudray C. Effects of long-term administration of saturated and n-3 fatty acid-rich diets on lipid utilisation and oxidative stress in rat liver and muscle tissues. Br J Nutr 110: 1789-1802, 2013.
67. Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, and Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 51: 3046-3054, 2010.
68. Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, Iwasa M, Watanabe S, and Takei Y. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 18: 424-432, 2009.
69. Gambino R, Musso G, and Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Re-dox Signal 15: 1325-1365, 2011.
70. Gazak R, Walterova D, and Kren V. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14: 315-338, 2007.
71. Gerber PA, Gouni-Berthold I, and Berneis K. Omega-3 fatty acids: role in metabolism and cardiovascular disease. Curr Pharm Des 19: 3074-3093, 2013.
72. Gnoni GV and Paglialonga G. Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest 39: 211-218, 2009.
73. Goto M, Kitamura H, Alam MM, Ota N, Haseba T, Akimoto T, Shimizu A, Takano-Yamamoto T, Yamamoto M, and Motohashi H. Alcohol dehydrogenase 3 contributes to the protection of liver from nonalcoholic steato-hepatitis. Genes Cells 20: 464-480, 2015.
74. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, and Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 19: 491-504, 2008.
75. Haddad Y, Vallerand D, Brault A, and Haddad PS. An-tioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Com-plement Alternat Med 2011: nep164, 2011.
76. Hajiaghamohammadi AA, Ziaee A, Oveisi S, and Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study. Hepat Mon 12: e6099, 2012.
77. Han YP, Kong M, Zheng S, Ren Y, Zhu L, Shi H, and Duan Z. Vitamin D in liver diseases: from mechanisms to clinical trials. J Gastroenterol Hepatol 28 Suppl 1: 49-55, 2013.
78. Haque JA, McMahan RS, Campbell JS, Shimizu-Albergine M, Wilson AM, Botta D, Bammler TK, Beyer RP, Montine TJ, Yeh MM, Kavanagh TJ, and Fausto N. Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Lab Invest 90: 1704-1717, 2010.
79. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ. Diversity in antioxidant response en-zymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38: 2293-2301, 2010.
80. Hargreaves IP. Coenzyme Q10 as a therapy for mito-chondrial disease. Int J Biochem Cell Biol 49: 105-111, 2014.
81. Harrison SA, Torgerson S, Hayashi P, Ward J, and Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2485-2490, 2003.
82. Hasegawa T, Yoneda M, Nakamura K, Makino I, and Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15: 1667-1672, 2001.
83. Hashemi M, Eskandari-Nasab E, Fazaeli A, Bahari A, Hashemzehi NA, Shafieipour S, Taheri M, Moazeni-Roodi A, Zakeri Z, Bakhshipour A, and Ghavami S. As-sociation of genetic polymorphisms of glutathione-S-transferase genes (GSTT1, GSTM1, and GSTP1) and susceptibility to nonalcoholic fatty liver disease in Zahe-dan, Southeast Iran. DNA Cell Biol 31: 672-677, 2012.
84. Hashemian Z, Hashemi A, and Fateminasab M. The benefits of vitamin E on liver function and the hemopoi-etic system in thalassemia patients. Iran J Ped Hematol Oncol 2: 153-158, 2012.
85. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Ka-wada N, Arakawa T, and Ueda M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43: 506-514, 2006.
86. Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, Yotsumoto K, Sakurai K, Iwashita H, Hirano G, Ueda SI, Yokoyama K, Morihara D, Nishizawa S, Anan A, Takeyama Y, Sakamoto M, Shakado S, and Sakisaka S. Levels of the oxidative stress marker gamma-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res 40: 924-933, 2012.
87. Ishigami A, Kondo Y, Nanba R, Ohsawa T, Handa S, Kubo S, Akita M, and Maruyama N. SMP30 deficiency in mice causes an accumulation of neutral lipids and phos-pholipids in the liver and shortens the life span. Biochem Biophys Res Commun 315: 575-580, 2004.
88. Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T, Sasaki J, Sasaki T, Watanabe S, Suzuki A, and Ohnishi H. Eicosapentae-noic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol 50: 562-571, 2009.
89. Jayaprakasam B, Olson LK, Schutzki RE, Tai MH, and Nair MG. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J Agric Food Chem 54: 243-248, 2006.
90. Jou J, Choi SS, and Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 28: 370-379, 2008.
91. Kasparova S, Sumbalova Z, Bystricky P, Kucharska J, Liptaj T, Mlynarik V, and Gvozdjakova A. Effect of co-enzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem Int 48: 93-99, 2006.
92. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD, and Kim JB. Ber-berine improves lipid dysregulation in obesity by con-trolling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 296: E812-E819, 2009.
93. Kitson MT and Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol 57: 897-909, 2012.
94. Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, Goldring CE, Powell H, Sanderson C, Williams S, Higgins L, Yamamoto M, Hayes J, and Park BK. Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics 73: 1612-1631, 2010.
95. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 77: 598-625, 2005.
96. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, and Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma co-enzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52: 934-944, 2010.
97. Kohli R, Pan X, Malladi P, Wainwright MS, and Whi-tington PF. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 282: 21327-21336, 2007.
98. Kondo Y, Inai Y, Sato Y, Handa S, Kubo S, Shimokado K, Goto S, Nishikimi M, Maruyama N, and Ishigami A. Senescence marker protein 30 functions as gluconolactonase in L-ascorbic acid biosynthesis, and its knockout mice are prone to scurvy. Proc Natl Acad Sci USA 103: 5723-5728, 2006.
99. Kondo Y and Ishigami A. Involvement of senescence marker protein-30 in glucose metabolism disorder and non-alcoholic fatty liver disease. Geriatr Gerontol Int 16 Suppl 1: 4-16, 2016.
100. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, Wang YM, Shan N, Zhou ZX, Yang P, You XF, Li ZR, Si SY, Zhao LX, Pan HN, and Jiang JD. Berberine reduces insulin resis-tance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 58: 109-119, 2009.
101. Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, and Ertugrul DT. The association of vitamin D deficiency with non-alcoholic fatty liver disease. Clinics (Sao Paulo) 69: 542-546, 2014.
102. Kushnareva Y, Murphy AN, and Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J 368: 545-553, 2002.
103. Lavine JE. Vitamin E treatment of nonalcoholic steatohepa-titis in children: a pilot study. J Pediatr 136: 734-738, 2000.
104. Le TH, Caldwell SH, Redick JA, Sheppard BL, Davis CA, Arseneau KO, Iezzoni JC, Hespenheide EE, Al-Osaimi A, and Peterson TC. The zonal distribution of mega-mitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 39: 1423-1429, 2004.
105. Lee JW, Choe SS, Jang H, Kim J, Jeong HW, Jo H, Jeong KH, Tadi S, Park MG, Kwak TH, Man Kim J, Hyun DH, and Kim JB. AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity. J Lipid Res 53: 1277-1286, 2012.
106. Lee YE, Kim JW, Lee EM, Ahn YB, Song KH, Yoon KH, Kim HW, Park CW, Li G, Liu Z, and Ko SH. Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS One 7: e50412, 2012.
107. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, and Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29: 113-119, 2009.
108. Li AN, Li S, Zhang YJ, Xu XR, Chen YM, and Li HB. Resources and biological activities of natural polyphenols. Nutrients 6: 6020-6047, 2014.
109. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, Desimone C, Song XY, and Diehl AM. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37: 343-350, 2003.
110. Lin YC, Chang PF, Hu FC, Chang MH, and Ni YH. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 124: e1221-e1227, 2009.
111. Liu S, Shi W, Li G, Jin B, Chen Y, Hu H, Liu L, Xie F, Chen K, and Yin D. Plasma reactive carbonyl species levels and risk of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 26: 1010-1015, 2011.
112. Liu Y, Song X, Han Y, Zhou F, Zhang D, Ji B, Hu J, Lv Y, Cai S, Wei Y, Gao F, and Jia X. Identification ofanthocyanin components of wild Chinese blueberries and amelioration of light-induced retinal damage in pigmented rabbit using whole berries. J Agric Food Chem 59: 356-363, 2011.
113. Liu Y, Wang D, Zhang D, Lv Y, Wei Y, Wu W, Zhou F, Tang M, Mao T, Li M, and Ji B. Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro. J Agric Food Chem 59: 12254-12263, 2011.
114. Liu Z, Jiang C, Zhang J, Liu B, and Du Q. Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. J Diabetes 8: 324-335, 2016.
115. Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Flor-eani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lo-bello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Del Vecchio Blanco C, and Federico A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 52: 1658-1665, 2012.
116. Loguercio C, De Simone T, D'Auria MV, de Sio I, Fed-erico A, Tuccillo C, Abbatecola AM, Del Vecchio Blanco C, and Italian ACG. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 36: 398-405, 2004.
117. Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Niosi M, D'Auria MV, Capasso R, Del Vecchio Blanco C, and Real Sud G. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 52: 2387-2395, 2007.
118. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, and Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gas-troenterol 39: 540-543, 2005.
119. Ma X, Hua J, and Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by in-creasing hepatic NKT cells. J Hepatol 49: 821-830, 2008.
120. Malaguarnera L, Madeddu R, Palio E, Arena N, and Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 42: 585-591, 2005.
121. Malhotra JD and Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal 9: 2277-2293, 2007.
122. Manco M, Calvani M, Nanni G, Greco AV, Iaconelli A, Gasbarrini G, Castagneto M, and Mingrone G. Low 25-hydroxyvitamin D does not affect insulin sensitivity in obesity after bariatric surgery. Obes Res 13: 1692-1700, 2005.
123. Mangge H, Becker K, Fuchs D, and Gostner JM. Anti-oxidants, inflammation and cardiovascular disease. World J Cardiol 6: 462-477, 2014.
124. Mann JP, De Vito R, Mosca A, Alisi A, Armstrong MJ, Raponi M, Baumann U, and Nobili V. Portal inflammation is independelty associated with fibrosis and metabolic syndrome in paediatric non-alcoholic fatty liver disease. Hepatology 63: 745-753, 2016.
125. Marcolin E, San-Miguel B, Vallejo D, Tieppo J, Marroni N, Gonzalez-Gallego J, and Tunon MJ. Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr 142: 1821-1828, 2012.
126. Masterton GS, Plevris JN, and Hayes PC. Review article: omega-3 fatty acids-a promising novel therapy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther 31: 679-692, 2010.
127. Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, Dinkova-Kostova AT, Dillon JF, Hayes JD, and Ashford ML. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol 34: 3305-3320, 2014.
128. Medjakovic S, Mueller M, and Jungbauer A. Potential health-modulating effects of isoflavones and metabolites via activation of PPAR and AhR. Nutrients 2: 241-279, 2010.
129. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142: 37-46, 2005.
130. Mohr D, Bowry VW, and Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 1126: 247-254, 1992.
131. Molendi-Coste O, Legry V, and Leclercq IA. Why and how meet n-3 PUFA dietary recommendations? Gastro-enterol Res Pract 2011: 364040, 2011.
132. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, and Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 47: 1167-1177, 2008.
133. Nadal-Casellas A, Amengual-Cladera E, Proenza AM, Llado I, and Gianotti M. Long-term high-fat-diet feeding impairs mitochondrial biogenesis in liver of male and female rats. Cell Physiol Biochem 26: 291-302, 2010.
134. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, and Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of stea-tohepatitis in mice fed a methionine-and choline-deficient diet. Eur J Pharmacol 536: 182-191, 2006.
135. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, Huang YZ, Honda H, Chen KD, Wang CC, Chiu KW, Jawan B, Eng HL, Goto S, and Chen CL. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 55: 415-425, 2011.
136. Nam HH, Jun DW, Jeon HJ, Lee JS, Saeed WK, and Kim EK. Osthol attenuates hepatic steatosis via decreased tri-glyceride synthesis not by insulin resistance. World J Gastroenterol 20: 11753-11761, 2014.
137. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Ne-moto Y, Ono M, Akisawa N, Saibara T, Hiroi M, Enzan H, and Onishi S. Polymorphisms of microsomal triglyc-eride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 40: 781-786, 2004.
138. Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, Zhao SX, Zhao JM, and Yu J. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol 44: 1121-1131, 2009.
139. Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, and Balasubramanyam M. Oxidative stress is independently associated with nonalcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 43: 815-821, 2010.
140. Nassir F and Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci 15: 8713-8742, 2014.
141. Nelson JE, Bhattacharya R, Lindor KD, Chalasani N, Raaka S, Heathcote EJ, Miskovsky E, Shaffer E, Rulyak SJ, and Kowdley KV. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 46: 723-729, 2007.
142. Nelson JE, Brunt EM, and Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology 56: 1730-1740, 2012.
143. Niki E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. Free Radic Biol Med 66: 3-12, 2014.
144. Niu X, Zhang H, Li W, Wang Y, Mu Q, Wang X, He Z, and Yao H. Protective effect of cavidine on acetic acid-induced murine colitis via regulating antioxidant, cytokine profile and NF-kappaB signal transduction pathways. Chem Biol Interact 239: 34-45, 2015.
145. Nobili V, Alisi A, Della Corte C, Rise P, Galli C, Agostoni C, and Bedogni G. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis 23: 1066-1070, 2013.
146. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, and Agostoni C. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96: 350-353, 2011.
147. Nobili V, Giorgio V, Liccardo D, Bedogni G, Morino G, Alisi A, and Cianfarani S. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 170: 547-553, 2014.
148. Nobili V, Parola M, Alisi A, Marra F, Piemonte F, Mombello C, Sutti S, Povero D, Maina V, Novo E, and Albano E. Oxidative stress parameters in paediatric nonalcoholic fatty liver disease. Int J Mol Med 26: 471-476, 2010.
149. Novo E, Busletta C, Bonzo LV, Povero D, Paternostro C, Mareschi K, Ferrero I, David E, Bertolani C, Caligiuri A, Cannito S, Tamagno E, Compagnone A, Colombatto S, Marra F, Fagioli F, Pinzani M, and Parola M. Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. J Hepatol 54: 964-974, 2011.
150. Okubo H, Sakoda H, Kushiyama A, Fujishiro M, Nakatsu Y, Fukushima T, Matsunaga Y, Kamata H, Asahara T, Yoshida Y, Chonan O, Iwashita M, Nishimura F, and Asano T. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am J Physiol Gastrointest Liver Physiol 305: G911-G918, 2013.
151. Oliveira CP and Stefano JT. Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): a mini review. Clin Res Hepatol Gastroenterol 39 Suppl 1: S35-S40, 2015.
152. Oliveira CP, Stefano JT, Cavaleiro AM, Zanella Fortes MA, Vieira SM, Rodrigues Lima VM, Santos TE, Santos VN, de Azevedo Salgado AL, Parise ER, Ferreira Alves VA, Carrilho FJ, and Correa-Giannella ML. Association of polymorphisms of glutamate-cystein ligase and mi-crosomal triglyceride transfer protein genes in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 25: 357-361, 2010.
153. Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, Smok G, and Videla LA. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cy-tochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 34: 57-63, 2006.
154. Pagliaro B, Santolamazza C, Simonelli F, and Rubattu S. Phytochemical Compounds and protection from cardiovascular diseases: a state of the art. Biomed Res Int 2015: 918069, 2015.
155. Panchal SK and Brown L. Cardioprotective and hepato-protective effects of ellagitannins from European oak bark (Quercus petraea L.) extract in rats. Eur J Nutr 52: 397-408, 2013.
156. Paredes-Lopez O, Cervantes-Ceja ML, Vigna-Perez M, and Hernandez-Perez T. Berries: improving human health and healthy aging, and promoting quality life-a review. Plant Foods Hum Nutr 65: 299-308, 2010.
157. Park HJ, Lee JY, Chung MY, Park YK, Bower AM, Koo SI, Giardina C, and Bruno RS. Green tea extract sup-presses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepa-titis. J Nutr 142: 57-63, 2012.
158. Pektas MB, Koca HB, Sadi G, and Akar F. Dietary fructose activates insulin signaling and inflammation in adipose tissue: modulatory role of resveratrol. Biomed Res Int 2016: 8014252, 2016.
159. Peng W, Ma YY, Zhang K, Zhou AY, Zhang Y, Wang H, Du Z, and Zhao DG. Synthesis and biological evaluation of novel resveratrol-NSAID derivatives as anti-inflammatory agents. Chem Pharm Bull (Tokyo) 64: 609-615, 2016.
160. Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, Colina F, Arenas J, and Solis-Herruzo JA. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. He-patology 38: 999-1007, 2003.
161. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22 Suppl 1: S20-S27, 2007.
162. Petrosillo G, Portincasa P, Grattagliano I, Casanova G, Matera M, Ruggiero FM, Ferri D, and Paradies G. Mi-tochondrial dysfunction in rat with nonalcoholic fatty liver involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta 1767: 1260-1267, 2007.
163. Petta S, Grimaudo S, Tripodo C, Cabibi D, Calvaruso M, Di Cristina A, Guarnotta C, Macaluso FS, Minissale MG, Marchesini G, and Craxi A. The hepatic expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 1 chronic hepatitis C patients. J Clin Endocrinol Metab 100: 193-200, 2015.
164. Phung N, Pera N, Farrell G, Leclercq I, Hou JY, and George J. Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary stea-tohepatitis. Int J Mol Med 24: 171-180, 2009.
165. Pirgon O, Bilgin H, Cekmez F, Kurku H, and Dundar BN. Association between insulin resistance and oxidative stress parameters in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 5: 33-39, 2013.
166. Polyak SJ, Oberlies NH, Pecheur EI, Dahari H, Ferenci P, and Pawlotsky JM. Silymarin for HCV infection. Antivir Ther 18: 141-147, 2013.
167. Raszeja-Wyszomirska J, Kurzawski G, Lawniczak M, Miezynska-Kurtycz J, and Lubinski J. Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. World J Gastroenterol 16: 2531-2536, 2010.
168. Reddy NM, Potteti HR, Mariani TJ, Biswal S, and Reddy SP. Conditional deletion of Nrf2 in airway epithelium exacerbates acute lung injury and impairs the resolution of inflammation. Am J Respir Cell Mol Biol 45: 1161-1168, 2011.
169. Rensen SS, Bieghs V, Xanthoulea S, Arfianti E, Bakker JA, Shiri-Sverdlov R, Hofker MH, Greve JW, and Buur-man WA. Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS One 7: e52411, 2012.
170. Rensen SS, Slaats Y, Nijhuis J, Jans A, Bieghs V, Driessen A, Malle E, Greve JW, and Buurman WA. In-creased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol 175: 1473-1482, 2009.
171. Ricci C, Pastukh V, Leonard J, Turrens J, Wilson G, Schaffer D, and Schaffer SW. Mitochondrial DNA damage triggers mitochondrial-superoxide generation and ap-optosis. Am J Physiol Cell Physiol 294: C413-C422, 2008.
172. Ritze Y, Bardos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, and Bischoff SC. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 9: e80169, 2014.
173. Rodriguez-Ramiro I, Vauzour D, and Minihane AM. Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms. Proc Nutr Soc 75: 47-60, 2016.
174. Rolo AP, Teodoro JS, and Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52: 59-69, 2012.
175. Rosado IV, Langevin F, Crossan GP, Takata M, and Patel KJ. Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. Nat Struct Mol Biol 18: 1432-1434, 2011.
176. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, and Kowdley KV. Vitamin D deficiency in obese rats exacerbates nonalco-holic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 55: 1103-1111, 2012.
177. Sakiyama H, Fujiwara N, Yoneoka Y, Yoshihara D, Eguchi H, and Suzuki K. Cu, Zn-SOD deficiency induces the accumulation of hepatic collagen. Free Radic Res 50: 666-677, 2016.
178. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, and Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res 159: 477-486, 2012.
179. Salamone F, Galvano F, Marino Gammazza A, Pa-ternostro C, Tibullo D, Bucchieri F, Mangiameli A, Parola M, Bugianesi E, and Li Volti G. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis 44: 334-342, 2012.
180. Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Pa-tumraj S, and Klaikeaw N. Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis. J Med Assoc Thai 90: 788-797, 2007.
181. Santos CX, Tanaka LY, Wosniak J, and Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 11: 2409-2427, 2009.
182. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR, and Nash CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685, 2010.
183. Sasidharan SR, Joseph JA, Anandakumar S, Venkatesan V, Madhavan CN, and Agarwal A. Ameliorative potential of Tamarindus indica on high fat diet induced nonalcoholic fatty liver disease in rats. Scientific World Journal 2014: 507197, 2014.
184. Satapathy SK and Sanyal AJ. Novel treatment modalities for nonalcoholic steatohepatitis. Trends Endocrinol Metab 21: 668-675, 2010.
185. Satapati S, Kucejova B, Duarte JA, Fletcher JA, Reynolds L, Sunny NE, He T, Nair LA, Livingston K, Fu X, Merritt ME, Sherry AD, Malloy CR, Shelton JM, Lambert J, Parks EJ, Corbin I, Magnuson MA, Browning JD, and Burgess SC. Mitochondrial metabolism mediates oxida-tive stress and inflammation in fatty liver. J Clin Invest 125: 4447-4462, 2015.
186. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, and Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 37: 56-62, 2002.
187. Sentman ML, Granstrom M, Jakobson H, Reaume A, Basu S, and Marklund SL. Phenotypes of mice lacking extracellular superoxide dismutase and copper-and zinc-containing superoxide dismutase. J Biol Chem 281: 6904-6909, 2006.
188. Serviddio G, Bellanti F, and Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med 65: 952-968, 2013.
189. Serviddio G, Bellanti F, Vendemiale G, and Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 5: 233-244, 2011.
190. Seymour EM, Singer AA, Kirakosyan A, Urcuyo-Llanes DE, Kaufman PB, and Bolling SF. Altered hyperlipidemia, hepatic steatosis, and hepatic peroxisome proliferator-activated receptors in rats with intake of tart cherry. J Med Food 11: 252-259, 2008.
191. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, and Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29: 698-706, 2008.
192. Sharifi N, Amani R, Hajiani E, and Cheraghian B. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine 47: 70-80, 2014.
193. Singal AK, Jampana SC, and Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int 31: 1432-1448, 2011.
194. Soden JS, Devereaux MW, Haas JE, Gumpricht E, Dahl R, Gralla J, Traber MG, and Sokol RJ. Subcutaneous vi-tamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology 46: 485-495, 2007.
195. Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, and Casini A. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 61: 792-802, 2010.
196. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, and Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 40: 194-199, 2008.
197. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, and Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408, 2006.
198. Starzynski RR, Lipinski P, Drapier JC, Diet A, Smuda E, Bartlomiejczyk T, Gralak MA, and Kruszewski M. Down-regulation of iron regulatory protein 1 activities and expression in superoxide dismutase 1 knock-out mice is not associated with alterations in iron metabolism. J Biol Chem 280: 4207-4212, 2005.
199. Strange RC, Shipman KE, and Ramachandran S. Metabolic syndrome: a review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes 6: 896-911, 2015.
200. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, Taguchi K, Yanagawa T, Nakahara A, Hyodo I, Ishii T, and Yamamoto M. Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 298: G283G294, 2010.
201. Sumida Y, Niki E, Naito Y, and Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res 47: 869-880, 2013.
202. Syn WK, Choi SS, and Diehl AM. Apoptosis and cyto-kines in non-alcoholic steatohepatitis. Clin Liver Dis 13: 565-580, 2009.
203. Tailleux A, Wouters K, and Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821: 809-818, 2012.
204. Takayama F, Nakamoto K, Totani N, Yamanushi T, Ka-buto H, Kaneyuki T, and Mankura M. Effects of doc-osahexaenoic acid in an experimental rat model of nonalcoholic steatohepatitis. J Oleo Sci 59: 407-414, 2010.
205. Takeuchi Y, Yahagi N, Izumida Y, Nishi M, Kubota M, Teraoka Y, Yamamoto T, Matsuzaka T, Nakagawa Y, Sekiya M, Iizuka Y, Ohashi K, Osuga J, Gotoda T, Ishi-bashi S, Itaka K, Kataoka K, Nagai R, Yamada N, Ka-dowaki T, and Shimano H. Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem 285: 11681-11691, 2010.
206. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, and Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 42: 413-418, 2008.
207. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 24: 1-6, 2007.
208. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, and Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17: 517-524, 2007.
209. Tariq Z, Green CJ, and Hodson L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepa-titis (NASH)? Liver Int 34: e180-e190, 2014.
210. Teodoro JS, Duarte FV, Gomes AP, Varela AT, Peixoto FM, Rolo AP, and Palmeira CM. Berberine reverts hepatic mi-tochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. Mitochondrion 13: 637-646, 2013.
211. Tessari P, Coracina A, Cosma A, and Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 19: 291-302, 2009.
212. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, and Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14: 612-622, 2011.
213. Tsuruta Y, Nagao K, Kai S, Tsuge K, Yoshimura T, Koganemaru K, and Yanagita T. Polyphenolic extract of lotus root (edible rhizome of Nelumbo nucifera) alleviates hepatic steatosis in obese diabetic db/db mice. Lipids Health Dis 10: 202, 2011.
214. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344, 2003.
215. Tzanetakou IP, Doulamis IP, Korou LM, Agrogiannis G, Vlachos IS, Pantopoulou A, Mikhailidis DP, Patsouris E, Vlachos I, and Perrea DN. Water soluble vitamin E ad-ministration in Wistar rats with non-alcoholic fatty liver disease. Open Cardiovasc Med J 6: 88-97, 2012.
216. Uchiyama S, Shimizu T, and Shirasawa T. CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J Biol Chem 281: 31713-31719, 2006.
217. Valenti L, Dongiovanni P, Fracanzani AL, Santorelli G, Fatta E, Bertelli C, Taioli E, Fiorelli G, and Fargion S. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. Dig Liver Dis 35: 172-178, 2003.
218. Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, and Fargion S. HFE genotype, parenchy-mal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138: 905-912, 2010.
219. Valenti L, Rametta R, Dongiovanni P, Motta BM, Cana-vesi E, Pelusi S, Pulixi EA, Fracanzani AL, and Fargion S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 7: e48804, 2012.
220. Valenzuela R, Espinosa A, Gonzalez-Manan D, D'Espessailles A, Fernandez V, Videla LA, and Tapia G. N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. PLoS One 7: e46400, 2012.
221. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, and Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49: 989-997, 2009.
222. Videla LA, Rodrigo R, Araya J, and Poniachik J. Insulin resistance and oxidative stress interdependency in nonalcoholic fatty liver disease. Trends Mol Med 12: 555-558, 2006.
223. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, Varela N, Contreras J, Lazarte R, Csendes A, Rojas J, Maluenda F, Burdiles P, Diaz JC, Smok G, Thielemann L, and Poniachik J. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 106: 261-268, 2004.
224. Vilar L, Oliveira CP, Faintuch J, Mello ES, Nogueira MA, Santos TE, Alves VA, and Carrilho FJ. High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects. Nutrition 24: 1097-1102, 2008.
225. Walenbergh SM, Koek GH, Bieghs V, and Shiri-Sverdlov R. Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol 58: 801-810, 2013.
226. Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, and Zhou XH. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 380: 644-649, 2009.
227. Wang L, Jiang Z, and Lei XG. Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogen-esis. Free Radic Biol Med 53: 1689-1696, 2012.
228. Wang N, Tan HY, Li L, Yuen MF, and Feng Y. Berberine and Coptidis Rhizoma as potential anticancer agents: recent updates and future perspectives. J Ethnopharmacol 176: 35-48, 2015.
229. Wang S, Kamat A, Pergola P, Swamy A, Tio F, and Cusi K. Metabolic factors in the development of hepatic stea-tosis and altered mitochondrial gene expression in vivo. Metabolism 60: 1090-1099, 2011.
230. Weber M, Baker MB, Moore JP, and Searles CD. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res Commun 393: 643-648, 2010.
231. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, Sowers JR, and Ibdah JA. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 49: 417-428, 2008.
232. Weltman MD, Farrell GC, and Liddle C. Increased he-patocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111: 1645-1653, 1996.
233. Wiedemann M, Kontush A, Finckh B, Hellwege HH, and Kohlschutter A. Neonatal blood plasma is less susceptible to oxidation than adult plasma owing to its higher content of bilirubin and lower content of oxidizable fatty acids. Pediatr Res 53: 843-849, 2003.
234. Wu KC, Cui JY, and Klaassen CD. Beneficial role of Nrf2 in regulating NADPH generation and consumption. Tox-icol Sci 123: 590-600, 2011.
235. Wu W, Xiao H, Laguna-Fernandez A, Villarreal G, Jr., Wang KC, Geary GG, Zhang Y, Wang WC, Huang HD, Zhou J, Li YS, Chien S, Garcia-Cardena G, and Shyy JY. Flow-dependent regulation of Kruppel-like factor 2 is mediated by microRNA-92a. Circulation 124: 633-641, 2011.
236. Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, and Tipoe GL. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in nonalcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr 53: 187-199, 2014.
237. Xu P, Wang H, Kayoumu A, Wang M, Huang W, and Liu G. Diet rich in docosahexaenoic acid/eicosapentaenoic acid robustly ameliorates hepatic steatosis and insulin resistance in seipin deficient lipodystrophy mice. Nutr Metab (Lond) 12: 58, 2015.
238. Xu YP, Liang L, Wang CL, Fu JF, Liu PN, Lv LQ, and Zhu YM. Association between UCP3 gene polymorphisms and nonalcoholic fatty liver disease in Chinese children. World J Gastroenterol 19: 5897-5903, 2013.
239. Xu YZ, Zhang X, Wang L, Zhang F, Qiu Q, Liu ML, Zhang GR, and Wu XL. An increased circulating angiotensin II concentration is associated with hypoadiponectinemia and postprandial hyperglycemia in men with nonalcoholic fatty liver disease. Intern Med 52: 855-861, 2013.
240. Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, Zeng MS, Tu YF, Feng R, Jia WP, Liu J, Deng W, Jiang JD, and Gao X. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One 10: e0134172, 2015.
241. Yang J, Yin J, Gao H, Xu L, Wang Y, Xu L, and Li M. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human pre-adipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med 2012: 363845, 2012.
242. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, and Kensler TW. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 30: 1024-1031, 2009.
243. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, Mu-sabak U, Erbil MK, Karaeren N, and Dagalp K. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 100: 850-855, 2005.
244. Yimin, Furumaki H, Matsuoka S, Sakurai T, Kohanawa M, Zhao S, Kuge Y, Tamaki N, and Chiba H. A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein. Lab Invest 92: 265-281, 2012.
245. Yogalakshmi B, Sreeja S, Geetha R, Radika MK, and Anuradha CV. Grape seed proanthocyanidin rescues rats from steatosis: a comparative and combination study with metformin. J Lipids 2013: 153897, 2013.
246. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, and Wymer M. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 64: 73-84, 2016.
247. Yu W, Fu YC, and Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113: 752-759, 2012.
248. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, and McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54: 1610-1619, 2011.
249. Zhang BJ, Xu D, Guo Y, Ping J, Chen LB, and Wang H. Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol 35: 303-309, 2008.
250. Zhang P, Qiang X, Zhang M, Ma D, Zhao Z, Zhou C, Liu X, Li R, Chen H, and Zhang Y. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mito-chondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther 352: 139-147, 2015.
251. Zhang Q, Liu J, Liu J, Huang W, Tian L, Quan J, Wang Y, and Niu R. oxLDL induces injury and defenestration of human liver sinusoidal endothelial cells via LOX1. J Mol Endocrinol 53: 281-293, 2014.
252. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, Li X, Ning G, and Zhao L. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 7: e42529, 2012.
253. Zhang YK, Yeager RL, Tanaka Y, and Klaassen CD. Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine-and choline-deficient diet. Toxicol Appl Pharmacol 245: 326-334, 2010.
254. Zhao HL, Sui Y, Qiao CF, Yip KY, Leung RK, Tsui SK, Lee HM, Wong HK, Zhu X, Siu JJ, He L, Guan J, Liu LZ, Xu HX, Tong PC, and Chan JC. Sustained antidiabetic effects of a berberine-containing Chinese herbal medicine through regulation of hepatic gene expression. Diabetes 61: 933-943, 2012.
255. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, Xu Y, Zhang L, and Li DD. Chronic effects of ber-berine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 31: 1169-1176, 2008.
256. Zhu FS, Liu S, Chen XM, Huang ZG, and Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlip-idemia. World J Gastroenterol 14: 6395-6400, 2008.